Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Future of chemotherapy].

M-O Grimm1, F H Hartmann, R Ackermann

  • 1Urologische Klinik, Heinrich-Heine-Universität, Moorenstrasse 5, 40225, Düsseldorf, Germany. marc-oliver.grimm@uni-duesseldorf.de

Der Urologe. Ausg. A
|May 20, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure.

ESMO open·2025
Same author

Larcher et al. The OpeRa trial: the active role of the patient in the clinical decision-making process and surgical planning.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients-exploratory results from TITAN-RCC.

ESMO open·2025
Same author

Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRa.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Future chemotherapy advances focus on predicting recurrence risk and personalized treatments. While adjuvant therapy shows promise, metastatic disease management emphasizes quality of life, with targeted drugs offering new avenues.

Area of Science:

  • Oncology
  • Pharmacology
  • Genomics

Context:

  • Chemotherapy evolution is driven by recent scientific breakthroughs.
  • Adjuvant therapy trends include standardized recurrence risk prediction using prognostic markers and molecular classifiers.

Purpose:

  • To review current advances in chemotherapy, focusing on adjuvant and metastatic disease treatment strategies.
  • To highlight the role of novel chemotherapeutic agents and targeted drugs.

Summary:

  • Adjuvant therapy is advancing with improved risk prediction and molecular profiling, alongside new drug regimens.
  • Metastatic disease survival breakthroughs are limited, shifting focus to quality of life improvements.
  • Targeted therapies show promise in both adjuvant and metastatic settings, pending better target-drug relationship understanding.

Related Experiment Videos

Impact:

  • Personalized medicine in oncology is advancing through molecular diagnostics and targeted drug development.
  • Improved patient outcomes and quality of life are anticipated with refined chemotherapy and targeted drug strategies.
  • Future treatment paradigms will likely integrate molecular profiling for precise therapeutic selection.